Alarming Rise in Breast and Cervical Cancers in Low- and Middle-Income Countries: Breaking Down Screening Barriers

By HEOR Staff Writer

July 5, 2023

Breast and cervical cancers are on the rise in low- and middle-income countries, with lower cure rates due to late diagnosis. Screening programs in these countries are not comprehensive, hindering early detection. 

By analysing studies published between 2016 and 2021, articles from low- and middle-income countries and using the 5A framework (approachability, acceptability, availability, affordability, and appropriateness), screening barriers were classified. 

Findings highlighted the lack of awareness, high screening costs, and distance to screening centers as major obstacles. Embarrassment, fear, and cultural factors also contribute to low screening rates. 

To combat these challenges, policymakers and governments must take action to enhance public confidence in healthcare systems. Evidence-based strategies are needed to educate women about cancer causes and risk factors, promoting increased adherence to screening. Together, we can make a difference in the fight against breast and cervical cancers worldwide.

Reference url

Recent Posts

Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package

By HEOR Staff Writer

February 9, 2026

Tislelizumab NSCLC Inclusion in Dutch Basic Package Zorginstituut Nederland's Tislelizumab NSCLC Inclusion Recommendation Zorginstituut Nederland's advisory report, dated February 4, 2026, recommends the...
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthrough Treatment

By HEOR Staff Writer

February 4, 2026

Datroway metastatic breast cancer treatment has gained Priority Review from the US Food and Drug Administration (FDA) for first-line use in adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) ineligible for PD-1/PD-L1 inhibitors. This milestone for AstraZeneca and ...
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies

By João L. Carapinha

February 2, 2026

CHMP January 2026 Approvals Signal Expanded Access to Innovative Therapies The CH...